GT Biopharma Inc (GTBP)

A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs

A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs...

Form PRE 14A - Other preliminary proxy statements

Form 8-K - Current report

After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell

Issued on behalf of GT Biopharma, Inc. Natural killer cells were long overshadowed by T-cell therapies. Now a...

Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet

Issued on behalf of GT Biopharma, Inc. (Nasdaq: GTBP) A clinical-stage immuno-oncology company has moved three...

The $13 Million Company Teaching the Immune System to Hunt Cancer

The $13 Million Company Teaching the Immune System to Hunt Cancer Canada NewsWire NEW YORK, May 29, 2026...

Form 8-K - Current report

Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes

Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes PR Newswire SAN FRANCISCO, May 19...

B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic

B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic Canada NewsWire SAN...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

"Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies

Issued on behalf of GT Biopharma, Inc. After more than $1.7 billion in dealmaking and a string of Phase 1...